[A case of advanced gastric cancer with pyloric stenosis and obstructive jaundice responding to s-1/paclitaxel combination therapy after endoscopic balloon dilatation and endoscopic biliary drainage].
A 65-year-old female who complained of appetite loss and upper abdominal pain was diagnosed as unresectable advanced gastric cancer with pyloric stenosis and obstructive jaundice by peritoneal and lymph node metastases. After endoscopic balloon dilatation and endoscopic biliary drainage, S-1(80 mg/m(2)/day, days 1-14 with 1 week rest)/pacli- taxel(PTX)(50 mg/m(2)/day, day 1, day 8)combination therapy was done. After one course of the chemotherapy, subjective symptoms were relieved and oral intake was increased. Computed tomography showed that the volume of gastric wall, the size of paraaortic lymph node, and the amount of pleural effusion and ascites were decreased. Grade 1 alopecia, vasculitis and grade 2 neutropenia were observed as adverse reactions to the treatment. S-1/PTX combination therapy after endoscopic intervention was effective in this case of advanced gastric cancer with pyloric stenosis and obstructive jaundice.
Ishii
Naoki
N
Dept. of Gastroenterology, St Luke's International Hospital.
Fujitani
Shino
S
Suzuki
Shoko
S
Tsukamoto
Masayo
M
Arai
Motoe
M
Hashimoto
Akemi
A
Izuka
Yusuke
Y
Fukuda
Katsuyuki
K
Horiki
Noriyuki
N
Fujita
Yoshiyuki
Y
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001660:Biliary Tract Diseases; D002404:Catheterization; D004338:Drug Combinations; D019723:Endoscopes; D005260:Female; D006801:Humans; D041781:Jaundice, Obstructive / Q000209:etiology / Q000473:pathology* / Q000628:therapy*; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D011707:Pyloric Stenosis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel